New KDIGO guidelines since 2021, Lupus Nephritis is seeing lots of new therapeutics in the pipeline.
Summary of the CAPTIVATE platform which will be a twitter spaces discussion
This week, we will discuss a registry trial: can a nationwide nudge fix a CKD treatment gap?
This week, we will discuss a pediatric nephrology trial: is tacrolimus superior to MMF in FRNS and SDNS?
This week, we will discuss a NEJM trial on uncontrolled hypertension: lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark side driving resistance.
New KDIGO guidelines since 2021, Lupus Nephritis is seeing lots of new therapeutics in the pipeline.
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) February 9, 2024
✳️10 tweets #NephJC catch-up ✳️
✴️Let’s recap the 2024 KDIGO Lupus Nephritis Guidelines!@BradRovin @AyuobIsabelle @meg21212 @cellotonelli @Gordon7Craig#KDIGO2024
❣️Didn’t get to join the 🐺pack for this one, no worries we’ll help you wolf it down 🥩! pic.twitter.com/Xg8NdWdH23